Therapy-associated polyposis was found to have similar features to various hereditary colorectal cancer symptoms, and recognition of it could have implications for cancer risk and screening among childhood and young adult cancer survivors.
Researchers indicated that a lack of understanding of the mechanism and efficacy of PD-1/PD-L1 inhibitors is the major barrier for prescription of these inhibitors in Chinese tumor treatment-related departments.
Researchers indicated that using observed incidence rates from patients with colorectal cancer alone to assess potential screening outcomes may underestimate cancer prevention benefits.
Postmenopausal women who had low perceived social support before their diagnosis had higher overall and CRC-specific mortality in this study.
The expert spoke about ongoing trials of novel treatment strategies that may lead to the development of new therapies in this space.
Given the data presented in this abstract, researchers indicated that it is crucial that further research works toward eliminating these disparities.
The patients with BRAF V600E-mutant metastatic colorectal cancer whose disease had progressed after 1 or 2 prior regimens reported substantial improvements in quality of life over the current standard of care.
Similar health risks for colorectal cancer were observed in both African Americans and whites, though this study indicated that benefit from greater adherence may be higher at the population level for African Americans.
Researchers indicated the importance in improving access to and uptake of CRC screening in these underserved populations.
Although researchers determined which regimen was preferred among physicians in treating metastatic colorectal cancer, they found that shared decision-making should include observation as an acceptable option.